CCL2 and neoplasm: Moreover, although the continuous blockade of macrophages constrains tumor progression, cessation of the CCL2 blocking therapy stimulates them to a rapid rebound, leading to accelerated metastatic disease via a mechanism dependent on VEGF-A and IL-6 production monocyte-derived by macrophages (102).